Sunny Linnebur
Concepts (335)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Geriatric Nursing | 4 | 2020 | 18 | 2.130 |
Why?
| | Geriatrics | 6 | 2025 | 96 | 1.520 |
Why?
| | Students, Pharmacy | 5 | 2025 | 96 | 1.170 |
Why?
| | Health Services for the Aged | 6 | 2018 | 70 | 1.140 |
Why?
| | Polypharmacy | 7 | 2026 | 93 | 1.100 |
Why?
| | Practice Guidelines as Topic | 7 | 2020 | 1563 | 1.090 |
Why?
| | Curriculum | 5 | 2024 | 1060 | 0.920 |
Why?
| | Education, Pharmacy | 6 | 2025 | 121 | 0.910 |
Why?
| | Nursing Homes | 7 | 2022 | 172 | 0.840 |
Why?
| | Aged, 80 and over | 32 | 2025 | 8279 | 0.800 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2024 | 136 | 0.760 |
Why?
| | Anticoagulants | 3 | 2018 | 724 | 0.760 |
Why?
| | Prescription Drugs | 3 | 2012 | 111 | 0.730 |
Why?
| | Pharmacists | 8 | 2021 | 240 | 0.700 |
Why?
| | Aged | 43 | 2025 | 25947 | 0.670 |
Why?
| | Aspirin | 1 | 2024 | 400 | 0.660 |
Why?
| | Aging | 4 | 2020 | 1966 | 0.630 |
Why?
| | Societies, Medical | 4 | 2025 | 887 | 0.630 |
Why?
| | Vitamin D Deficiency | 4 | 2012 | 186 | 0.630 |
Why?
| | Muscular Diseases | 1 | 2020 | 108 | 0.600 |
Why?
| | Bone Diseases | 1 | 2020 | 61 | 0.600 |
Why?
| | Vitamin D | 5 | 2016 | 400 | 0.590 |
Why?
| | Hyponatremia | 2 | 2016 | 43 | 0.570 |
Why?
| | Medication Therapy Management | 3 | 2023 | 73 | 0.570 |
Why?
| | Vitamin K | 1 | 2018 | 45 | 0.540 |
Why?
| | Safety | 1 | 2019 | 356 | 0.520 |
Why?
| | Warfarin | 2 | 2009 | 170 | 0.510 |
Why?
| | Automobile Driving | 1 | 2019 | 157 | 0.510 |
Why?
| | Interprofessional Relations | 1 | 2019 | 281 | 0.500 |
Why?
| | Osteoporosis | 2 | 2010 | 236 | 0.490 |
Why?
| | Humans | 76 | 2026 | 144957 | 0.480 |
Why?
| | Chemical and Drug Induced Liver Injury | 2 | 2010 | 139 | 0.470 |
Why?
| | Bupropion | 1 | 2016 | 47 | 0.460 |
Why?
| | Internet | 2 | 2025 | 700 | 0.460 |
Why?
| | Self Report | 2 | 2017 | 873 | 0.450 |
Why?
| | Educational Measurement | 5 | 2025 | 326 | 0.440 |
Why?
| | Hypercholesterolemia | 2 | 2025 | 93 | 0.420 |
Why?
| | Health Literacy | 1 | 2016 | 184 | 0.410 |
Why?
| | Drug Therapy | 3 | 2017 | 80 | 0.410 |
Why?
| | Antidepressive Agents | 1 | 2016 | 248 | 0.410 |
Why?
| | Vitamins | 3 | 2016 | 178 | 0.410 |
Why?
| | Health Status | 1 | 2019 | 836 | 0.400 |
Why?
| | Drug Monitoring | 2 | 2024 | 395 | 0.400 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2025 | 439 | 0.390 |
Why?
| | Pragmatic Clinical Trials as Topic | 3 | 2022 | 133 | 0.380 |
Why?
| | Health Personnel | 2 | 2019 | 748 | 0.380 |
Why?
| | Colorado | 10 | 2024 | 4564 | 0.380 |
Why?
| | Long-Term Care | 3 | 2022 | 117 | 0.370 |
Why?
| | Delivery of Health Care | 1 | 2020 | 947 | 0.370 |
Why?
| | Urinary Retention | 1 | 2012 | 25 | 0.370 |
Why?
| | Cholinergic Antagonists | 1 | 2012 | 23 | 0.370 |
Why?
| | Prostatic Hyperplasia | 1 | 2012 | 40 | 0.360 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2012 | 73 | 0.360 |
Why?
| | Cross Infection | 2 | 2011 | 262 | 0.350 |
Why?
| | Drug Approval | 1 | 2012 | 91 | 0.350 |
Why?
| | Pharmacy Service, Hospital | 2 | 2019 | 81 | 0.350 |
Why?
| | Antihypertensive Agents | 1 | 2015 | 511 | 0.350 |
Why?
| | Health Communication | 1 | 2012 | 54 | 0.350 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1186 | 0.350 |
Why?
| | Male | 37 | 2026 | 72406 | 0.340 |
Why?
| | Physicians | 2 | 2020 | 940 | 0.340 |
Why?
| | Lower Urinary Tract Symptoms | 1 | 2012 | 59 | 0.340 |
Why?
| | Atherosclerosis | 2 | 2025 | 409 | 0.330 |
Why?
| | Schools, Pharmacy | 2 | 2024 | 47 | 0.330 |
Why?
| | Proton Pump Inhibitors | 2 | 2024 | 109 | 0.330 |
Why?
| | Medication Adherence | 4 | 2024 | 539 | 0.320 |
Why?
| | Female | 38 | 2026 | 78376 | 0.320 |
Why?
| | Grifola | 1 | 2009 | 1 | 0.310 |
Why?
| | Herb-Drug Interactions | 1 | 2009 | 4 | 0.310 |
Why?
| | Central Nervous System Agents | 1 | 2009 | 7 | 0.310 |
Why?
| | International Normalized Ratio | 1 | 2009 | 49 | 0.310 |
Why?
| | Pain | 4 | 2018 | 782 | 0.290 |
Why?
| | Renal Insufficiency | 2 | 2016 | 169 | 0.290 |
Why?
| | Central Nervous System Diseases | 1 | 2009 | 74 | 0.290 |
Why?
| | Blood Pressure | 1 | 2015 | 1769 | 0.290 |
Why?
| | Fractures, Bone | 3 | 2016 | 415 | 0.290 |
Why?
| | United States | 11 | 2025 | 15988 | 0.290 |
Why?
| | Patient Education as Topic | 3 | 2012 | 780 | 0.280 |
Why?
| | Pneumonia | 2 | 2011 | 631 | 0.280 |
Why?
| | Accidental Falls | 3 | 2025 | 222 | 0.270 |
Why?
| | Depression | 3 | 2018 | 1559 | 0.270 |
Why?
| | Dementia | 2 | 2024 | 304 | 0.260 |
Why?
| | Drug Interactions | 4 | 2018 | 401 | 0.260 |
Why?
| | Dental Care for Chronically Ill | 1 | 2007 | 10 | 0.260 |
Why?
| | Bone and Bones | 1 | 2010 | 315 | 0.260 |
Why?
| | Faculty, Dental | 1 | 2007 | 8 | 0.260 |
Why?
| | Hypertension | 1 | 2015 | 1264 | 0.250 |
Why?
| | Erectile Dysfunction | 1 | 2006 | 38 | 0.250 |
Why?
| | Education, Dental | 1 | 2007 | 35 | 0.240 |
Why?
| | Testis | 1 | 2007 | 163 | 0.240 |
Why?
| | Dietary Supplements | 1 | 2010 | 576 | 0.240 |
Why?
| | Chronic Disease | 5 | 2026 | 1813 | 0.230 |
Why?
| | Primary Prevention | 2 | 2025 | 220 | 0.230 |
Why?
| | Urinary Tract Infections | 2 | 2019 | 203 | 0.220 |
Why?
| | Community Pharmacy Services | 1 | 2005 | 46 | 0.220 |
Why?
| | Cholinesterase Inhibitors | 1 | 2005 | 46 | 0.220 |
Why?
| | Patient Advocacy | 1 | 2005 | 74 | 0.220 |
Why?
| | Education, Distance | 1 | 2025 | 61 | 0.220 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2016 | 338 | 0.210 |
Why?
| | Diphosphonates | 1 | 2004 | 68 | 0.210 |
Why?
| | Nitrofurantoin | 1 | 2004 | 9 | 0.210 |
Why?
| | Cognitive Dysfunction | 2 | 2021 | 464 | 0.210 |
Why?
| | Fluconazole | 1 | 2004 | 23 | 0.210 |
Why?
| | Retrospective Studies | 14 | 2024 | 17101 | 0.200 |
Why?
| | Cholecalciferol | 2 | 2016 | 60 | 0.200 |
Why?
| | Research Design | 1 | 2009 | 1137 | 0.190 |
Why?
| | Middle Aged | 14 | 2024 | 35928 | 0.190 |
Why?
| | Antifungal Agents | 1 | 2004 | 149 | 0.190 |
Why?
| | Smoking Cessation | 1 | 2006 | 439 | 0.190 |
Why?
| | Secondary Prevention | 1 | 2024 | 255 | 0.190 |
Why?
| | Cyclohexanols | 1 | 2002 | 10 | 0.180 |
Why?
| | Professional Role | 4 | 2018 | 158 | 0.180 |
Why?
| | Vaginal Diseases | 1 | 2002 | 18 | 0.180 |
Why?
| | Research | 1 | 2005 | 431 | 0.180 |
Why?
| | Age Factors | 5 | 2015 | 3335 | 0.180 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2002 | 44 | 0.180 |
Why?
| | Nonprescription Drugs | 2 | 2016 | 65 | 0.180 |
Why?
| | Caregivers | 2 | 2026 | 1049 | 0.170 |
Why?
| | Administration, Oral | 3 | 2018 | 848 | 0.170 |
Why?
| | United States Food and Drug Administration | 2 | 2012 | 205 | 0.170 |
Why?
| | Ergocalciferols | 2 | 2012 | 14 | 0.170 |
Why?
| | Academic Medical Centers | 1 | 2024 | 548 | 0.170 |
Why?
| | Prevalence | 4 | 2017 | 2836 | 0.170 |
Why?
| | Artificial Intelligence | 1 | 2025 | 367 | 0.170 |
Why?
| | Anti-Bacterial Agents | 1 | 2011 | 1915 | 0.160 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2024 | 497 | 0.160 |
Why?
| | Self Care | 2 | 2014 | 389 | 0.160 |
Why?
| | Methenamine | 1 | 2019 | 4 | 0.160 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2019 | 16 | 0.150 |
Why?
| | Smoking | 1 | 2006 | 1472 | 0.150 |
Why?
| | Education, Continuing | 1 | 2019 | 41 | 0.150 |
Why?
| | Diet | 1 | 2007 | 1275 | 0.150 |
Why?
| | Patients | 2 | 2011 | 182 | 0.150 |
Why?
| | Surveys and Questionnaires | 5 | 2024 | 6053 | 0.150 |
Why?
| | Cross-Sectional Studies | 4 | 2024 | 5872 | 0.140 |
Why?
| | Risk Factors | 4 | 2025 | 10792 | 0.140 |
Why?
| | Sexism | 1 | 2019 | 70 | 0.140 |
Why?
| | Alzheimer Disease | 1 | 2005 | 622 | 0.140 |
Why?
| | Pharmacy | 1 | 2019 | 33 | 0.140 |
Why?
| | Recreation | 1 | 2018 | 27 | 0.140 |
Why?
| | Transitional Care | 1 | 2019 | 46 | 0.140 |
Why?
| | Physicians, Women | 1 | 2019 | 88 | 0.140 |
Why?
| | Melatonin | 1 | 2019 | 163 | 0.140 |
Why?
| | Drug Therapy, Combination | 2 | 2015 | 1048 | 0.140 |
Why?
| | Drug Prescriptions | 2 | 2010 | 285 | 0.130 |
Why?
| | Independent Living | 1 | 2018 | 114 | 0.130 |
Why?
| | Medication Reconciliation | 2 | 2019 | 31 | 0.130 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2017 | 12 | 0.130 |
Why?
| | Patient Transfer | 1 | 2020 | 206 | 0.130 |
Why?
| | Lung Diseases | 1 | 2004 | 787 | 0.130 |
Why?
| | Problem-Based Learning | 2 | 2017 | 98 | 0.130 |
Why?
| | Adult | 10 | 2026 | 40506 | 0.130 |
Why?
| | Hemorrhage | 1 | 2002 | 809 | 0.120 |
Why?
| | Guideline Adherence | 2 | 2011 | 589 | 0.120 |
Why?
| | Health Education | 2 | 2016 | 358 | 0.120 |
Why?
| | Refuse Disposal | 1 | 2016 | 4 | 0.120 |
Why?
| | Patient-Centered Care | 2 | 2023 | 544 | 0.120 |
Why?
| | Telemedicine | 1 | 2025 | 948 | 0.120 |
Why?
| | Qualitative Research | 1 | 2024 | 1671 | 0.120 |
Why?
| | Ibuprofen | 1 | 2016 | 84 | 0.120 |
Why?
| | Cohort Studies | 3 | 2015 | 5965 | 0.120 |
Why?
| | Ambulatory Care Facilities | 1 | 2018 | 266 | 0.120 |
Why?
| | Emergency Service, Hospital | 2 | 2025 | 2313 | 0.120 |
Why?
| | Primary Health Care | 2 | 2024 | 1734 | 0.120 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2015 | 42 | 0.110 |
Why?
| | Sleep Wake Disorders | 1 | 2019 | 302 | 0.110 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1327 | 0.110 |
Why?
| | Leadership | 1 | 2019 | 409 | 0.110 |
Why?
| | Cardiovascular Diseases | 2 | 2024 | 2171 | 0.110 |
Why?
| | Child Health | 1 | 2016 | 157 | 0.110 |
Why?
| | Kansas | 2 | 2011 | 28 | 0.110 |
Why?
| | Sodium | 1 | 2016 | 197 | 0.110 |
Why?
| | Marijuana Use | 1 | 2018 | 213 | 0.110 |
Why?
| | Missouri | 2 | 2011 | 66 | 0.110 |
Why?
| | Cognition Disorders | 1 | 2018 | 538 | 0.110 |
Why?
| | Pharmaceutical Preparations | 1 | 2016 | 170 | 0.100 |
Why?
| | Faculty, Medical | 1 | 2017 | 303 | 0.100 |
Why?
| | Creatinine | 2 | 2007 | 506 | 0.100 |
Why?
| | Priapism | 1 | 2013 | 10 | 0.100 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 2013 | 19 | 0.100 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2013 | 34 | 0.100 |
Why?
| | Hypoglycemic Agents | 2 | 2014 | 1389 | 0.100 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2013 | 18 | 0.100 |
Why?
| | Ambulatory Care | 3 | 2008 | 603 | 0.100 |
Why?
| | Nursing Staff | 2 | 2010 | 41 | 0.100 |
Why?
| | Blood Glucose | 2 | 2014 | 2330 | 0.100 |
Why?
| | Proline | 1 | 2013 | 83 | 0.100 |
Why?
| | Patient Care Team | 2 | 2011 | 689 | 0.100 |
Why?
| | Hoarding | 1 | 2012 | 1 | 0.100 |
Why?
| | Program Evaluation | 1 | 2017 | 949 | 0.090 |
Why?
| | Respiratory Tract Infections | 1 | 2016 | 398 | 0.090 |
Why?
| | Assisted Living Facilities | 2 | 2016 | 19 | 0.090 |
Why?
| | Atrial Fibrillation | 1 | 2018 | 550 | 0.090 |
Why?
| | Teaching | 1 | 2014 | 236 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 2 | 2011 | 1358 | 0.090 |
Why?
| | Education, Nursing, Continuing | 1 | 2011 | 52 | 0.090 |
Why?
| | Electronic Health Records | 3 | 2014 | 1177 | 0.080 |
Why?
| | Kidney | 1 | 2019 | 1496 | 0.080 |
Why?
| | Stakeholder Participation | 2 | 2022 | 84 | 0.080 |
Why?
| | Administration, Inhalation | 1 | 2012 | 575 | 0.080 |
Why?
| | Interpersonal Relations | 1 | 2014 | 400 | 0.080 |
Why?
| | Prognosis | 1 | 2019 | 4293 | 0.080 |
Why?
| | Glucosamine | 1 | 2010 | 14 | 0.080 |
Why?
| | Chondroitin Sulfates | 1 | 2010 | 35 | 0.080 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 45 | 0.080 |
Why?
| | Parathyroid Hormone | 2 | 2008 | 112 | 0.080 |
Why?
| | Piracetam | 1 | 2009 | 14 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 783 | 0.080 |
Why?
| | Blood Chemical Analysis | 1 | 2010 | 109 | 0.070 |
Why?
| | Conflict of Interest | 1 | 2009 | 53 | 0.070 |
Why?
| | Hip Fractures | 1 | 2010 | 84 | 0.070 |
Why?
| | Infection Control | 1 | 2010 | 172 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2014 | 2584 | 0.070 |
Why?
| | Stroke | 1 | 2018 | 1258 | 0.070 |
Why?
| | Mass Screening | 3 | 2018 | 1348 | 0.070 |
Why?
| | Immunization Programs | 1 | 2010 | 194 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1721 | 0.070 |
Why?
| | Drug Dosage Calculations | 1 | 2008 | 27 | 0.070 |
Why?
| | Delphi Technique | 1 | 2009 | 331 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 732 | 0.070 |
Why?
| | Anticonvulsants | 1 | 2009 | 242 | 0.060 |
Why?
| | Nutrition Policy | 1 | 2007 | 58 | 0.060 |
Why?
| | Anxiety Disorders | 1 | 2010 | 373 | 0.060 |
Why?
| | Heptanoic Acids | 1 | 2007 | 67 | 0.060 |
Why?
| | Simvastatin | 1 | 2007 | 60 | 0.060 |
Why?
| | Phosphorus | 1 | 2007 | 99 | 0.060 |
Why?
| | Grounded Theory | 1 | 2026 | 46 | 0.060 |
Why?
| | Orthodontics, Corrective | 1 | 2006 | 8 | 0.060 |
Why?
| | Serum Albumin | 1 | 2007 | 147 | 0.060 |
Why?
| | Comorbidity | 1 | 2011 | 1660 | 0.060 |
Why?
| | Premedication | 1 | 2006 | 42 | 0.060 |
Why?
| | Isoxazoles | 1 | 2006 | 54 | 0.060 |
Why?
| | Decision Making | 2 | 2011 | 980 | 0.060 |
Why?
| | Child | 3 | 2026 | 22657 | 0.060 |
Why?
| | Pyrroles | 1 | 2007 | 218 | 0.060 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2005 | 55 | 0.060 |
Why?
| | Inpatients | 1 | 2010 | 546 | 0.060 |
Why?
| | Life Expectancy | 1 | 2005 | 72 | 0.060 |
Why?
| | Metabolic Clearance Rate | 1 | 2004 | 115 | 0.050 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2005 | 80 | 0.050 |
Why?
| | Medical Records Systems, Computerized | 1 | 2005 | 95 | 0.050 |
Why?
| | Adolescent | 5 | 2026 | 22453 | 0.050 |
Why?
| | Onychomycosis | 1 | 2004 | 3 | 0.050 |
Why?
| | Tablets | 1 | 2024 | 41 | 0.050 |
Why?
| | Bone Diseases, Metabolic | 1 | 2004 | 56 | 0.050 |
Why?
| | Influenza, Human | 1 | 2010 | 617 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2016 | 1416 | 0.050 |
Why?
| | Hematologic Diseases | 1 | 2004 | 66 | 0.050 |
Why?
| | Communication | 3 | 2016 | 967 | 0.050 |
Why?
| | Heart Failure | 1 | 2017 | 2323 | 0.050 |
Why?
| | Outpatients | 1 | 2007 | 443 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2025 | 358 | 0.050 |
Why?
| | Patient Discharge | 2 | 2020 | 983 | 0.050 |
Why?
| | Data Collection | 1 | 2005 | 635 | 0.050 |
Why?
| | Time Factors | 2 | 2011 | 7183 | 0.050 |
Why?
| | Rheumatic Diseases | 1 | 2004 | 97 | 0.050 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2002 | 12 | 0.050 |
Why?
| | Menstruation | 1 | 2002 | 42 | 0.050 |
Why?
| | Pharmaceutical Services | 2 | 2016 | 78 | 0.040 |
Why?
| | Health Care Costs | 1 | 2005 | 427 | 0.040 |
Why?
| | Algorithms | 1 | 2010 | 1839 | 0.040 |
Why?
| | Sulfonamides | 1 | 2006 | 581 | 0.040 |
Why?
| | Quality of Life | 2 | 2023 | 3192 | 0.040 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2021 | 16 | 0.040 |
Why?
| | Palliative Care | 1 | 2010 | 1008 | 0.040 |
Why?
| | Calcium | 1 | 2007 | 1184 | 0.040 |
Why?
| | Liver Diseases | 1 | 2004 | 304 | 0.040 |
Why?
| | Nervous System Diseases | 1 | 2004 | 284 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2032 | 0.040 |
Why?
| | Hospitalization | 1 | 2010 | 2434 | 0.040 |
Why?
| | Child, Preschool | 2 | 2026 | 11799 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2019 | 157 | 0.040 |
Why?
| | Analgesics, Opioid | 1 | 2008 | 1143 | 0.040 |
Why?
| | Depressive Disorder | 1 | 2002 | 387 | 0.040 |
Why?
| | Healthcare Financing | 1 | 2018 | 6 | 0.040 |
Why?
| | Protons | 1 | 2019 | 95 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 1054 | 0.040 |
Why?
| | Biomarkers | 1 | 2010 | 4275 | 0.030 |
Why?
| | Guidelines as Topic | 2 | 2010 | 268 | 0.030 |
Why?
| | Anxiety | 2 | 2018 | 1110 | 0.030 |
Why?
| | Prospective Studies | 2 | 2007 | 7997 | 0.030 |
Why?
| | Double-Blind Method | 2 | 2016 | 2029 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2018 | 233 | 0.030 |
Why?
| | Nephrology Nursing | 1 | 2016 | 15 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2017 | 282 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 760 | 0.030 |
Why?
| | Skilled Nursing Facilities | 1 | 2016 | 151 | 0.030 |
Why?
| | Education, Medical, Undergraduate | 1 | 2017 | 207 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2019 | 514 | 0.030 |
Why?
| | Patient Readmission | 1 | 2020 | 759 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1890 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2018 | 1137 | 0.030 |
Why?
| | Obesity | 1 | 2007 | 3082 | 0.020 |
Why?
| | Cardiomyopathies | 1 | 2017 | 338 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2013 | 93 | 0.020 |
Why?
| | Medical Audit | 1 | 2013 | 77 | 0.020 |
Why?
| | Medicare | 1 | 2018 | 887 | 0.020 |
Why?
| | Drug Evaluation | 1 | 2012 | 79 | 0.020 |
Why?
| | Neoplasms | 1 | 2008 | 2884 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1495 | 0.020 |
Why?
| | Comprehension | 1 | 2014 | 180 | 0.020 |
Why?
| | Sleep | 1 | 2019 | 901 | 0.020 |
Why?
| | Educational Status | 1 | 2014 | 467 | 0.020 |
Why?
| | Drug Therapy, Computer-Assisted | 1 | 2011 | 12 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2019 | 11695 | 0.020 |
Why?
| | Electronic Mail | 1 | 2011 | 61 | 0.020 |
Why?
| | Pharmacies | 1 | 2011 | 42 | 0.020 |
Why?
| | Personal Autonomy | 1 | 2011 | 59 | 0.020 |
Why?
| | Disclosure | 1 | 2011 | 85 | 0.020 |
Why?
| | Decision Trees | 1 | 2010 | 81 | 0.020 |
Why?
| | Midwestern United States | 1 | 2010 | 45 | 0.020 |
Why?
| | Medical Informatics | 1 | 2011 | 97 | 0.020 |
Why?
| | Complementary Therapies | 1 | 2011 | 94 | 0.020 |
Why?
| | Massage | 1 | 2010 | 42 | 0.020 |
Why?
| | Medication Errors | 1 | 2010 | 83 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2009 | 5417 | 0.020 |
Why?
| | Hypoglycemia | 1 | 2014 | 477 | 0.020 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 257 | 0.020 |
Why?
| | Epilepsies, Partial | 1 | 2009 | 63 | 0.020 |
Why?
| | Clinical Competence | 1 | 2016 | 1244 | 0.020 |
Why?
| | Young Adult | 2 | 2017 | 14126 | 0.020 |
Why?
| | Self Administration | 1 | 2008 | 124 | 0.020 |
Why?
| | Administration, Cutaneous | 1 | 2008 | 125 | 0.020 |
Why?
| | Oxycodone | 1 | 2008 | 53 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2008 | 183 | 0.020 |
Why?
| | Morphine | 1 | 2008 | 171 | 0.020 |
Why?
| | Fentanyl | 1 | 2008 | 127 | 0.020 |
Why?
| | Orthodontic Wires | 1 | 2006 | 6 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2010 | 901 | 0.010 |
Why?
| | Pain Management | 1 | 2010 | 405 | 0.010 |
Why?
| | Methadone | 1 | 2008 | 122 | 0.010 |
Why?
| | Kidney Diseases | 1 | 2009 | 427 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2006 | 427 | 0.010 |
Why?
| | Pain Measurement | 1 | 2006 | 555 | 0.010 |
Why?
| | Sex Factors | 1 | 2006 | 2114 | 0.010 |
Why?
|
|
Linnebur's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|